Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC.PVLA · Entity 4452 | Director | October 12, 2026 | October 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PALVELLA THERAPEUTICS, INC.
Report date October 12, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 132,616 |
Ending reported balance
After 2026-10-14 transaction · row 17
17 source rows · reconciled sequenceRow 1 · 2026-10-12 · Sale · Disposed 5,095 · Balance 155,021 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $131.91 to $132.9064, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 2 · 2026-10-12 · Sale · Disposed 2,458 · Balance 152,563 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $132.91 to $133.9078, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 3 · 2026-10-12 · Sale · Disposed 3,335 · Balance 149,228 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $133.9184 to $134.9182, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 4 · 2026-10-12 · Sale · Disposed 1,447 · Balance 147,781 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $134.9283 to $135.8712, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 5 · 2026-10-12 · Sale · Disposed 817 · Balance 146,964 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $135.9387 to $136.8346, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 6 · 2026-10-13 · Sale · Disposed 2,004 · Balance 144,960 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $127.91 to $128.865, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 7 · 2026-10-13 · Sale · Disposed 1,644 · Balance 143,316 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F8: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $128.915 to $129.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 8 · 2026-10-13 · Sale · Disposed 990 · Balance 142,326 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F9: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $130.00 to $130.855, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 9 · 2026-10-13 · Sale · Disposed 1,035 · Balance 141,291 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F10: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $131.07 to $132.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 10 · 2026-10-13 · Sale · Disposed 579 · Balance 140,712 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F11: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $132.07 to $133.045, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 11 · 2026-10-13 · Sale · Disposed 922 · Balance 139,790 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F12: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $133.11 to $134.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 12 · 2026-10-14 · Sale · Disposed 476 · Balance 139,314 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F13: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $120.7075 to $121.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 13 · 2026-10-14 · Sale · Disposed 2,072 · Balance 137,242 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F14: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $121.90 to $122.8795, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 14 · 2026-10-14 · Sale · Disposed 2,604 · Balance 134,638 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F15: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $122.903 to $123.8032, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 15 · 2026-10-14 · Sale · Disposed 920 · Balance 133,718 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F16: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $123.91 to $124.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 16 · 2026-10-14 · Sale · Disposed 597 · Balance 133,121 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F17: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $124.99 to $125.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 17 · 2026-10-14 · Sale · Disposed 505 · Balance 132,616 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F18: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $126.13 to $127.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
| Common StockSEC Table I · non-derivative | IndirectBy foundation | 13,516 |
Reported balance
Holding disclosure · report date 2026-10-12 · row 18
Holding and transaction disclosures are not merged.
1 source rowRow 18 · Balance 13,516 F19: Eagles Mere Air Museum Foundation. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $131.91 to $132.9064, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $132.91 to $133.9078, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $133.9184 to $134.9182, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $134.9283 to $135.8712, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $135.9387 to $136.8346, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $127.91 to $128.865, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F8: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $128.915 to $129.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F9: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $130.00 to $130.855, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F10: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $131.07 to $132.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F11: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $132.07 to $133.045, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F12: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $133.11 to $134.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F13: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $120.7075 to $121.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F14: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $121.90 to $122.8795, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F15: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $122.903 to $123.8032, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F16: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $123.91 to $124.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F17: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $124.99 to $125.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F18: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $126.13 to $127.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F19: Eagles Mere Air Museum Foundation.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 14, 2026 Filed Oct 14, 2026 23:14 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 505 | $126.55 | $63,910.17 |
DisclosureSEC source: 0001104659-26-115916 · tm2627587-1_4seq1.xml · nonDerivative · entry 17 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,616 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F18 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $126.13 to $127.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 14, 2026 Filed Oct 14, 2026 23:14 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 597 | $125.33 | $74,820.28 |
DisclosureSEC source: 0001104659-26-115916 · tm2627587-1_4seq1.xml · nonDerivative · entry 16 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,121 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F17 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $124.99 to $125.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 14, 2026 Filed Oct 14, 2026 23:14 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 920 | $124.37 | $114,415.98 |
DisclosureSEC source: 0001104659-26-115916 · tm2627587-1_4seq1.xml · nonDerivative · entry 15 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,718 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F16 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $123.91 to $124.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 14, 2026 Filed Oct 14, 2026 23:14 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 2,604 | $123.29 | $321,046.12 |
DisclosureSEC source: 0001104659-26-115916 · tm2627587-1_4seq1.xml · nonDerivative · entry 14 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,638 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F15 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $122.903 to $123.8032, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 14, 2026 Filed Oct 14, 2026 23:14 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 2,072 | $122.62 | $254,058.49 |
DisclosureSEC source: 0001104659-26-115916 · tm2627587-1_4seq1.xml · nonDerivative · entry 13 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,242 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F14 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $121.90 to $122.8795, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 14, 2026 Filed Oct 14, 2026 23:14 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 476 | $121.14 | $57,662.78 |
DisclosureSEC source: 0001104659-26-115916 · tm2627587-1_4seq1.xml · nonDerivative · entry 12 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,314 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F13 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $120.7075 to $121.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 13, 2026 Filed Oct 14, 2026 23:14 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 922 | $133.72 | $123,292.33 |
DisclosureSEC source: 0001104659-26-115916 · tm2627587-1_4seq1.xml · nonDerivative · entry 11 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,790 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F12 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $133.11 to $134.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 13, 2026 Filed Oct 14, 2026 23:14 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 579 | $132.40 | $76,662.26 |
DisclosureSEC source: 0001104659-26-115916 · tm2627587-1_4seq1.xml · nonDerivative · entry 10 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,712 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F11 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $132.07 to $133.045, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 13, 2026 Filed Oct 14, 2026 23:14 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 1,035 | $131.49 | $136,092.15 |
DisclosureSEC source: 0001104659-26-115916 · tm2627587-1_4seq1.xml · nonDerivative · entry 9 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,291 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $131.07 to $132.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 13, 2026 Filed Oct 14, 2026 23:14 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 990 | $130.48 | $129,175.40 |
DisclosureSEC source: 0001104659-26-115916 · tm2627587-1_4seq1.xml · nonDerivative · entry 8 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,326 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $130.00 to $130.855, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 13, 2026 Filed Oct 14, 2026 23:14 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 1,644 | $129.23 | $212,454.94 |
DisclosureSEC source: 0001104659-26-115916 · tm2627587-1_4seq1.xml · nonDerivative · entry 7 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,316 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $128.915 to $129.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 13, 2026 Filed Oct 14, 2026 23:14 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 2,004 | $128.52 | $257,555.28 |
DisclosureSEC source: 0001104659-26-115916 · tm2627587-1_4seq1.xml · nonDerivative · entry 6 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,960 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $127.91 to $128.865, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 12, 2026 Filed Oct 14, 2026 23:14 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 817 | $136.44 | $111,475.07 |
DisclosureSEC source: 0001104659-26-115916 · tm2627587-1_4seq1.xml · nonDerivative · entry 5 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,964 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $135.9387 to $136.8346, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 12, 2026 Filed Oct 14, 2026 23:14 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 1,447 | $135.50 | $196,063.87 |
DisclosureSEC source: 0001104659-26-115916 · tm2627587-1_4seq1.xml · nonDerivative · entry 4 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,781 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $134.9283 to $135.8712, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 12, 2026 Filed Oct 14, 2026 23:14 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 3,335 | $134.21 | $447,585.68 |
DisclosureSEC source: 0001104659-26-115916 · tm2627587-1_4seq1.xml · nonDerivative · entry 3 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,228 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $133.9184 to $134.9182, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 12, 2026 Filed Oct 14, 2026 23:14 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 2,458 | $133.25 | $327,524.32 |
DisclosureSEC source: 0001104659-26-115916 · tm2627587-1_4seq1.xml · nonDerivative · entry 2 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 152,563 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $132.91 to $133.9078, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 12, 2026 Filed Oct 14, 2026 23:14 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 5,095 | $132.62 | $675,681.07 |
DisclosureSEC source: 0001104659-26-115916 · tm2627587-1_4seq1.xml · nonDerivative · entry 1 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 155,021 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $131.91 to $132.9064, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 15, 2026 Filed Sep 16, 2026 01:15 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 560 | $151.33 | $84,742.73 |
DisclosureSEC source: 0001104659-26-108022 · tm2625443-1_4seq1.xml · nonDerivative · entry 9 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 160,116 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F2 · kind: Any profit required to be disgorged under Section 16 of the Securities Exchange Act of 1934, as amended, with respect to an aggregate of 445 shares sold in the transactions reported on this Form 4 will be disgorged to the Issuer pursuant to applicable requirements. F11 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $151.16 to $151.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 15, 2026 Filed Sep 16, 2026 01:15 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 263 | $150.40 | $39,556.38 |
DisclosureSEC source: 0001104659-26-108022 · tm2625443-1_4seq1.xml · nonDerivative · entry 8 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 160,676 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F2 · kind: Any profit required to be disgorged under Section 16 of the Securities Exchange Act of 1934, as amended, with respect to an aggregate of 445 shares sold in the transactions reported on this Form 4 will be disgorged to the Issuer pursuant to applicable requirements. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $150.0525 to $151.0225, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 15, 2026 Filed Sep 16, 2026 01:15 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 954 | $149.38 | $142,506.52 |
DisclosureSEC source: 0001104659-26-108022 · tm2625443-1_4seq1.xml · nonDerivative · entry 7 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 160,939 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F2 · kind: Any profit required to be disgorged under Section 16 of the Securities Exchange Act of 1934, as amended, with respect to an aggregate of 445 shares sold in the transactions reported on this Form 4 will be disgorged to the Issuer pursuant to applicable requirements. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $148.90 to $149.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 14, 2026 Filed Sep 16, 2026 01:15 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 1,560 | $153.10 | $238,834.44 |
DisclosureSEC source: 0001104659-26-108022 · tm2625443-1_4seq1.xml · nonDerivative · entry 6 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,893 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F2 · kind: Any profit required to be disgorged under Section 16 of the Securities Exchange Act of 1934, as amended, with respect to an aggregate of 445 shares sold in the transactions reported on this Form 4 will be disgorged to the Issuer pursuant to applicable requirements. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $152.88 to $153.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 14, 2026 Filed Sep 16, 2026 01:15 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 6,160 | $152.12 | $937,033.94 |
DisclosureSEC source: 0001104659-26-108022 · tm2625443-1_4seq1.xml · nonDerivative · entry 5 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 163,453 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F2 · kind: Any profit required to be disgorged under Section 16 of the Securities Exchange Act of 1934, as amended, with respect to an aggregate of 445 shares sold in the transactions reported on this Form 4 will be disgorged to the Issuer pursuant to applicable requirements. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $151.80 to $152.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 14, 2026 Filed Sep 16, 2026 01:15 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 5,632 | $151.46 | $853,036.80 |
DisclosureSEC source: 0001104659-26-108022 · tm2625443-1_4seq1.xml · nonDerivative · entry 4 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 169,613 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F2 · kind: Any profit required to be disgorged under Section 16 of the Securities Exchange Act of 1934, as amended, with respect to an aggregate of 445 shares sold in the transactions reported on this Form 4 will be disgorged to the Issuer pursuant to applicable requirements. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $150.80 to $151.785, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 11, 2026 Filed Sep 16, 2026 01:15 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 1,274 | $153.06 | $194,997.29 |
DisclosureSEC source: 0001104659-26-108022 · tm2625443-1_4seq1.xml · nonDerivative · entry 3 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 175,245 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F2 · kind: Any profit required to be disgorged under Section 16 of the Securities Exchange Act of 1934, as amended, with respect to an aggregate of 445 shares sold in the transactions reported on this Form 4 will be disgorged to the Issuer pursuant to applicable requirements. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $152.42 to $153.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 11, 2026 Filed Sep 16, 2026 01:15 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 4,577 | $151.72 | $694,402.76 |
DisclosureSEC source: 0001104659-26-108022 · tm2625443-1_4seq1.xml · nonDerivative · entry 2 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 176,519 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F2 · kind: Any profit required to be disgorged under Section 16 of the Securities Exchange Act of 1934, as amended, with respect to an aggregate of 445 shares sold in the transactions reported on this Form 4 will be disgorged to the Issuer pursuant to applicable requirements. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $151.23 to $152.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 11, 2026 Filed Sep 16, 2026 01:15 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 6,520 | $150.62 | $982,035.23 |
DisclosureSEC source: 0001104659-26-108022 · tm2625443-1_4seq1.xml · nonDerivative · entry 1 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,096 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F2 · kind: Any profit required to be disgorged under Section 16 of the Securities Exchange Act of 1934, as amended, with respect to an aggregate of 445 shares sold in the transactions reported on this Form 4 will be disgorged to the Issuer pursuant to applicable requirements. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $150.23 to $151.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 16:07 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | GrantStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $102.19 | $0.00 |
DisclosureSEC source: 0001104659-26-073442 · tm2617372-5_4seq1.xml · derivative · entry 1 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: The shares subject to this option shall vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the Issuer's next annual meeting of stockholders following the grant date, subject in each case to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 16:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | PurchaseCommon Stock | 445 | $112.30 | $49,973.50 |
DisclosureSEC source: 0001104659-26-038496 · tm2610145-3_4seq1.xml · nonDerivative · entry 1 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,616 Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 08:00 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | PurchaseCommon Stock | 4,000 | $125.00 | $500,000.00 |
DisclosureSEC source: 0001104659-26-021922 · tm267613-2_4seq1.xml · nonDerivative · entry 1 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,171 F1 · shares: Represents shares of common stock purchased in the underwritten offering of Palvella Therapeutics, Inc. at the offering price, which closed on February 27, 2026. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 19:59 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,350 | $0.00 Strike: $26.23 | $0.00 |
DisclosureSEC source: 0001583648-25-000040 · edgardoc.xml · derivative · entry 1 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,350 Underlying: Common Stock · 12,350 shares Expires 2035-06-10 Read SEC document |
| April 09, 2025 Filed Apr 10, 2025 19:06 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | PurchaseCommon Stock | 2,490 | $20.27 | $50,472.30 |
DisclosureSEC source: 0001583648-25-000025 · edgardoc.xml · nonDerivative · entry 2 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · by foundation Disclosed balance after: 13,516 F1 · ownership.nature: Eagles Mere Air Museum Foundation Read SEC document |
| April 09, 2025 Filed Apr 10, 2025 19:06 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | PurchaseCommon Stock | 2,500 | $20.13 | $50,325.00 |
DisclosureSEC source: 0001583648-25-000025 · edgardoc.xml · nonDerivative · entry 1 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,171 Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 10:23 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | PurchaseCommon Stock | 4,000 | $12.93 | $51,720.00 |
DisclosureSEC source: 0001062993-24-020879 · form4.xml · nonDerivative · entry 1 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,671 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.59 to $13.09, inclusive. The reporting person undertakes to provide to Palvella Therapeutics, Inc., any security holder of Palvella Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| December 13, 2024 Filed Dec 17, 2024 20:42 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | GrantStock Option (right to buy) · Derivative | 24,700 | $0.00 Strike: $13.60 | $0.00 |
DisclosureSEC source: 0001062993-24-020817 · form4.xml · derivative · entry 1 JENKINS GEORGE M · CIK 0001271081 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,700 Underlying: Common Stock · 24,700 shares Expires 2034-12-13 F1 · derivative.exercise_date: The stock options will vest and become exercisable in 36 equal monthly installments through the third anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.